metaPreg - Hydroxychloroquine (Indication Antiphospholipid Syndrom) during pregnancy

Hydroxychloroquine (Indication Antiphospholipid Syndrom)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	0.39 [0.03, 4.81]	0%	2 studies	1	149	not evaluable	ROB
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Small for gestational age (weight)	0.42 [0.18, 0.99]	2%	3 studies	33	216	not evaluable	ROB
Preterm (< 37 weeks)	0.45 [0.09, 2.11]	71%	2 studies	56	146	not evaluable	ROB
Low birth weight (< 2500g)	0.42 [0.22, 0.83]	-	1 study	47	112	not evaluable	ROB
1 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Preeclampsia	0.32 [0.14, 0.70]	0%	4 studies	46	241	not evaluable	ROB
Caesarean	0.50 [0.29, 0.86]	0%	2 studies	66	82	not evaluable	ROB
Maternal consequences (as a whole)	0.32 [0.14, 0.72]	-	1 study	35	94	not evaluable	ROB
2 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Low Apgar score (< 7) (at 5 min)	0.38 [0.19, 0.75]	-	1 study	22	33	not evaluable	ROB
4 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Intrauterine deaths (as a whole or unspecified)	0.37 [0.21, 0.65]	56%	7 studies	493	437	not evaluable	ROB
Early intrauterine death (< 22 weeks)	0.29 [0.09, 0.95]	79%	3 studies	110	246	not evaluable	ROB
1 non statistically significant endpoints reported in only one study